Download PDF
Pharmacopsychiatry 2013; 46(07): 274-280
DOI: 10.1055/s-0033-1354405
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence of Medication Use for Somatic Disease in Institutionalized Psychiatric Patients

H. Abdullah-Koolmees
1   Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
2   Altrecht Institute for Mental Health Care, Den Dolder and Utrecht, The Netherlands
,
H. Gardarsdottir
1   Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
3   Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
,
L. J. Stoker
2   Altrecht Institute for Mental Health Care, Den Dolder and Utrecht, The Netherlands
,
J. Vuyk
2   Altrecht Institute for Mental Health Care, Den Dolder and Utrecht, The Netherlands
,
T. C. G. Egberts
1   Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
3   Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
,
E. R. Heerdink
1   Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
2   Altrecht Institute for Mental Health Care, Den Dolder and Utrecht, The Netherlands
3   Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

received 27 March 2013
revised 06 August 2013

accepted 10 August 2013

Publication Date:
08 October 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction:

Psychiatric patients may use medications for their psychiatric condition as well as for treating concurrent somatic diseases or somatic side effects of psychiatric medicines. The objective of this study was to estimate the prevalence of use of medication for somatic disease in institutionalized psychiatric patients and changes therein during 2006–2010.

Method:

A cross-sectional study in institutionalized psychiatric patients was performed. Medication use for somatic disease on 10 time points between 2006 and 2010 was investigated and stratified by gender, age, psychiatric medication class and the number of different psychiatric medication classes used.

Results:

The prevalence of use of medication for somatic disease increased from 67.5% in 2006 to 76.9% in 2010. The median number of medications used for somatic disease per patient was 3 between 2006 and 2010. Approximately one-third (34.1%) of the patients received ≥3 medications intended for treating somatic disease in 2006 which increased to 46.3% in 2010. In 2010, the prevalence of medication use for somatic disease was highest for analgesics and antirheumatics (34.0%), acid and bowel related medication (25.6%) and anticholinergic medication (24.2%). Medication use for somatic disease was highest in patients ≥60 years (95.3%), patients treated with more than one psychiatric medication class (87.5%) and patients treated with mood stabilizers (90.6%).

Discussion:

Somatic medication use is high in institutionalized psychiatric patients. More attention is needed for co-use of psychiatric and somatic medications to prevent side effects, drug-disease or drug-drug interactions. More research is needed to investigate if somatic care is optimal in institutionalized psychiatric patients.

Key words

prevalence - somatic medication - psychiatric patients - drug intraction

Supplementary information

 

  • References

  • 1 De Hert M, van Winkel R, Silic A et al. Physical health management in psychiatric settings. Eur Psychiatry 2010; 25 (Suppl. 02) S22-S28
    CrossrefPubMedGoogle Scholar
  • 2 Haueis P, Greil W, Huber M et al. Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software. Clin Pharmacol Ther 2011; 90: 588-596
    CrossrefPubMedGoogle Scholar
  • 3 American Diabetes Association . American Psychiatric Association, American Association of Clinical Endocrinologists et al . Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 2004; 27: 596-601
    PubMedGoogle Scholar
  • 4 De Hert M, Vancampfort D, Correll CU et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199: 99-105
    CrossrefPubMedGoogle Scholar
  • 5 Iacovides A, Siamouli M. Comorbid mental and somatic disorders: an epidemiological perspective. Curr Opin Psychiatry 2008; 21: 417-421
    CrossrefPubMedGoogle Scholar
  • 6 Dixon L, Postrado L, Delahanty J et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187: 496-502
    Google Scholar
  • 7 Miller BJ, Paschall 3rd CB, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57: 1482-1487
    CrossrefPubMedGoogle Scholar
  • 8 Mookhoek EJ, Van De Kerkhof PC, Hovens JE et al. Skin disorders in chronic psychiatric illness. J Eur Acad Dermatol Venereol 2010; 24: 1151-1156
    CrossrefPubMedGoogle Scholar
  • 9 Katsamanis M, Lehrer PM, Escobar JI et al. Psychophysiologic treatment for patients with medically unexplained symptoms: a randomized controlled trial. Psychosomatics 2011; 52: 218-229
    CrossrefPubMedGoogle Scholar
  • 10 Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry 1991; 148: 1494-1500
    PubMedGoogle Scholar
  • 11 Walker EA, Roy-Byrne PP, Katon WJ. Irritable bowel syndrome and psychiatric illness. Am J Psychiatry 1990; 147: 565-572
    PubMedGoogle Scholar
  • 12 Walker EA, Roy-Byrne PP, Katon WJ et al. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry 1990; 147: 1656-1661
    PubMedGoogle Scholar
  • 13 Andreski P, Chilcoat H, Breslau N. Post-traumatic stress disorder and somatization symptoms: a prospective study. Psychiatry Res 1998; 79: 131-138
    CrossrefPubMedGoogle Scholar
  • 14 Engel Jr CC, Liu X, McCarthy BD et al. Relationship of physical symptoms to posttraumatic stress disorder among veterans seeking care for gulf war-related health concerns. Psychosom Med 2000; 62: 739-745
    PubMedGoogle Scholar
  • 15 Deary IJ. A taxonomy of medically unexplained symptoms. J Psychosom Res 1999; 47: 51-59
    CrossrefPubMedGoogle Scholar
  • 16 Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21: 517-535
    CrossrefPubMedGoogle Scholar
  • 17 Stoklosa J, Ongur D. Rational antipsychotic choice: weighing the risk of tardive dyskinesia and metabolic syndrome. Harv Rev Psychiatry 2011; 19: 271-276
    CrossrefPubMedGoogle Scholar
  • 18 Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging 2012; 29: 15-30
    CrossrefPubMedGoogle Scholar
  • 19 Sylvestre MP, Abrahamowicz M, Capek R et al. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. Int Psychogeriatr 2011; 1-10
    PubMedGoogle Scholar
  • 20 Crews MP, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol 2012; 27: 15-23
    CrossrefPubMedGoogle Scholar
  • 21 Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21: 449-456
    CrossrefPubMedGoogle Scholar
  • 22 Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29: 259-266
    CrossrefPubMedGoogle Scholar
  • 23 Shim JC, Shin JG, Kelly DL et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404-1410
    CrossrefPubMedGoogle Scholar
  • 24 Cohen D, Bonnot O, Bodeau N et al. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol 2012; 32: 309-316
    CrossrefPubMedGoogle Scholar
  • 25 Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93
    Google Scholar
  • 26 Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005; 19: 102-109
    PubMedGoogle Scholar
  • 27 Kreyenbuhl J, Buchanan RW, Dickerson FB et al. Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010; 36: 94-103
    CrossrefPubMedGoogle Scholar
  • 28 Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010; 122: 1-23
    CrossrefPubMedGoogle Scholar
  • 29 National Institute for Health and Clinical Excellence . Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Nice 2009; Available at: http://www.nice.org.uk/CG82quickrefguide
    PubMedGoogle Scholar
  • 30 Altrecht MHC. Annual Report 2010 of Altrecht/Jaardocument 2010 2010; 19-94
    PubMed
  • 31 WHO . Collaborating Centre for Drug Statistics Methodology . Guidelines for ATC classification and DDD assignment 2011. 2010;
    PubMedGoogle Scholar
  • 32 Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ et al. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol 2009; 68: 187-193
    CrossrefPubMedGoogle Scholar
  • 33 Schorre BE, Vandvik IH. Global assessment of psychosocial functioning in child and adolescent psychiatry. A review of three unidimensional scales (CGAS, GAF, GAPD). Eur Child Adolesc Psychiatry 2004; 13: 273-286
    PubMedGoogle Scholar
  • 34 The Health Care Insurance Board GIP databank. Accessed July 2, 2012
    PubMed
  • 35 Bushardt RL, Massey EB, Simpson TW et al. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008; 3: 383-389
    PubMedGoogle Scholar
  • 36 Bergk V, Gasse C, Rothenbacher D et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96
    CrossrefPubMedGoogle Scholar
  • 37 Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy 2006; 26: 1307-1313
    CrossrefPubMedGoogle Scholar
  • 38 Vandraas KF, Spigset O, Mahic M et al. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010; 66: 823-829
    CrossrefPubMedGoogle Scholar
  • 39 Leendertse AJ, Egberts AC, Stoker LJ et al., HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-1896
    CrossrefPubMedGoogle Scholar
  • 40 Goedhard LE, Stolker JJ, Nijman HL et al. Aggression of psychiatric patients associated with the use of as-needed medication. Pharmacopsychiatry 2007; 40: 25-29
    Article in Thieme ConnectPubMedGoogle Scholar